Pazopanib for the treatment of renal cancer

Bibliography

• Jemal A, Siegel R, Ward E, Cancer Statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   PubMed Web of Science ®Google Scholar
• Linehan WM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003;170(6 Pt 1):2163-72
   PubMedGoogle Scholar
• Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22(24):4991-5004
   PubMed Web of Science ®Google Scholar
• Linehan WM, Zbar B, Bates BE, Cancer of the kidney and ureter. In: deVita VTHS, Rosenberg SA, editors, Cancer principles and practice of oncology. 6th edition. Lippincott Williams and Wilkins, Philadelphia, PA; 2001. p. 1362-96
   Google Scholar
• Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353(23):2477-90
   PubMedGoogle Scholar
• Fisher RIRS, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(Suppl 1):S55-7
   PubMed Web of Science ®Google Scholar
• Rini BI. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 2009;115(S10):2306-12
   PubMedGoogle Scholar
• Gnarra JR, Tory K, Weng Y, Mutations of the VHL tumour suppressor gene in renal carcinoma.. Nat Genet 1994;7(1):85-90
   PubMed Web of Science ®Google Scholar
• Schraml P, Struckmann K, Hatz F, VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear-cell renal cell carcinoma. J Pathol 2002;196(2):186-93
   PubMedGoogle Scholar
• Gallou C, Joly D, Méjean A, Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999;13(6):464-75
   PubMedGoogle Scholar
• Ainsworth NL, Lee JS, Eisen T. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2009;9(12):1793-805
   PubMedGoogle Scholar
• Rini BI, Michaelson MD, Rosenberg JE, Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26(22):3743-8
   PubMed Web of Science ®Google Scholar
• Rasmuson T, Grankvist K, Jacobsen J, Ljungberg B. Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur J Cancer 2001;37(17):2199-203
   PubMedGoogle Scholar
• Wechsel HWBK, Feil G, Loeser W, Renal cell carcinoma: relevance of angiogenetic factors. Anticancer Res 1999;19(2C):1537-40
   PubMedGoogle Scholar
• Rennel ES, Harper SJ, Bates DO. Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncol 2009;5(5):703-12
   PubMedGoogle Scholar
• Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 2006;63(5):601-15
   PubMedGoogle Scholar
• Yang JC, Haworth L, Sherry RM, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Negrier S, Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28(13):2144-50
   PubMedGoogle Scholar
• Rini BI, Halabi S, Rosenberg JE, Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137-43
   PubMed Web of Science ®Google Scholar
• Raymond E, Faivre S, Vera K, Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 2003;22:192
   Google Scholar
• Strumberg D, Richly H, Hilger RA, Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-72
   PubMed Web of Science ®Google Scholar
• Rini BIWG, Hudes G, Stadler WM, Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):5032
   Google Scholar
• Hurwitz HI, Dowlati A, Saini S, Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15(12):4220-7
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90
   PubMed Web of Science ®Google Scholar
• Limvorasak S, Posadas EM. Pazopanib: therapeutic developments. Expert Opin Pharmacother 2009;10(18):3091-102
   PubMedGoogle Scholar
• Sonpavde G, Hutson TE, Sternberg CN. Pazopanib for the treatment of renal cell carcinoma and other malignancies. Drugs Today (Barc) 2009;45(9):651-61
   PubMedGoogle Scholar
• Kumar R, Knick VB, Rudolph SK, Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6(7):2012-21
   PubMed Web of Science ®Google Scholar
• Votrient (pazopanib) [package insert]. Research Triangle Park NG
   Google Scholar
• Shibata SLJ, Chung VM, Lenz H, A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD). J Clin Oncol 2010;28(15S): abstract 2571
   PubMedGoogle Scholar
• Dejonge MSS, Verweij J, Collins TS, A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. J Clin Oncol 2006;24(142S): abstract 3088
   Google Scholar
• Tan ARJS, Dowlati A, Levinson K, Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034). J Clin Oncol 2008;26(20 Suppl): abstract 3552
   Google Scholar
• Hutson TE, Davis ID, Machiels J-PH, Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28(3):475-80
   PubMed Web of Science ®Google Scholar
• Suttle B, Ball HA, Molimard M, Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC). J Clin Oncol 2010;28(15S): abstract 3048
   Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
   PubMed Web of Science ®Google Scholar
• Sternberg CN. Pazopanib in renal cell carcinoma. Clin Adv Hematol Oncol 2010;8(4):232-3
   PubMedGoogle Scholar
• Xu C-F, Reck BH, Xue Z, Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. British Journal of Cancer 2010;102(9):1371-7
   PubMedGoogle Scholar
• Motzer RJ, Mazumdar M, Bacik J, Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530
   PubMed Web of Science ®Google Scholar
• Mekhail TM, Abou-Jawde RM, BouMerhi G, Validation and extension of the memorial sloan-kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23(4):832-41
   PubMedGoogle Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
   PubMed Web of Science ®Google Scholar
• DePrimo S, Bello C, Smeraglia J, Soluble protein biomarkers of pharmacodynamic activity of the multi-targeted kinase inhibitor SU11248 in patients with metastatic renal cell cancer. Proc Am Assoc Cancer Res 2005;46:108
   Google Scholar
• Escudier B, Szczylik C, Hutson TE, Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(8):1280-9
   PubMed Web of Science ®Google Scholar
• Votrient (pazopanib) [package insert] Research Triangle Park, NC: GlaxoSmithKline; October 2009
   Google Scholar
• Votrient. Drug Facts and Comparisons. Facts & Comparisons® eAnswers [online]. 2010. Available from: http://www.tuftshealthplan.com/providers/pdf/pharmacy_criteria/votrient.pdf. Wolters Kluwer Health, Inc. [Accessed 1 February 2010]
   Google Scholar
• Lang JM, Harrison MR. Pazopanib for the treatment of patients with advanced cell carcinoma. Clin Med Insights Oncol 2010;4:95-105
   PubMedGoogle Scholar
• ClinicalTrials.gov online. Available from: http://clinicaltrials.gov/
   Google Scholar
• Selleckchem.com online. Available from: http://www.selleckchem.com/
   Google Scholar
• Varella L, Rini BI. Emerging drugs for renal cell carcinoma. Expert Opin Emerg Drugs 2010;15(3):343-53
   PubMedGoogle Scholar
• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 373:1119-32
   PubMedGoogle Scholar
• Motzer RJ, Hutson TE, Tomczak P, Phase III randomized trial of sunitinib maleate (SU11248) versus interferon-alfa (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (RCC). 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S):LBA3
   Google Scholar
• Mischinger J, Froehlich E. Prognostic relevance of B7H1 and B7H3 protein expressions in metastatic clear cell renal cell carcinoma. ASCO 2010 Abstract e15074 from Department of Urology, Medical University of Graz, Graz, Austria; Center for Medical Research
   Google Scholar
• Kim JJ, Vaziri SA, Elson P, Rini BI. General Poster Session, Genitourinary Cancer ASCO 2010 [abstract No: 4629]. J Clin Oncol 2010;28(15S): abstract 4629
   Google Scholar
• Hainsworth JD, Spigel DR. A phase II trial of pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab [abstract]. ASCO 2010
   Google Scholar
• Ball HA, Xu C, Sternberg CN. Association of germ-line genetic markers in IL8, HIF1A, VEGFA, and VEGFR2 with treatment response to pazopanib in renal cell carcinoma [abstract 4520]. ASCO 2010; GlaxoSmithKline
   Google Scholar
• Tran HT, Liu Y, Lin Y. Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients [abstract 4522]. ASCO 2010
   Google Scholar
• Kim JJ, Vaziri SA, Elson P, Rini BI. VEGF single nucleotide polymorphisms (SNPs) and correlation to baseline and sunitinib-induced hypertension (HTN) in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract 330]. ASCO 2010
   Google Scholar
• Sternberg CN. Randomised, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (MRCC), ESMO: Pazopanib in advanced MRCC – late breaker published 11/10/2010 by ecancer reporter Jo Armstrong
   Google Scholar
• Xu CF, Reck BH, Goodman VL, Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. [PubMed: PMID: 21145803; J Hepatology 2011 Feb 12; Published by Elsevier B.V]
   Google Scholar